Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-10-01

Clinical Trial Update: A Study of TG103 Injection in Overweight/Obese Subjects With Type 2 Diabetes [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for TG103 Injection in overweight/obese subjects with Type 2 Diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TG103 Injection

Snippet

Sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Conditions: Type 2 Diabetes Mellitus | Phase 2 | Status: UNKNOWN